Form 8-K - Current report:
SEC Accession No. 0001628280-24-046399
Filing Date
2024-11-07
Accepted
2024-11-07 17:09:54
Documents
15
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20241107.htm   iXBRL 8-K 28254
2 EX-99.1 a2024q3-ex991er.htm EX-99.1 247142
6 GRAPHIC cumberlandpharmaimageaa06a.jpg GRAPHIC 37721
  Complete submission text file 0001628280-24-046399.txt   476929

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20241107.xsd EX-101.SCH 1894
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20241107_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20241107_pre.xml EX-101.PRE 12611
17 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20241107_htm.xml XML 2724
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 241437008
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)